Idera Pharmaceuticals downgraded by Barclays with a new price target

3/19/21 7:12:17 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Barclays downgraded Idera Pharmaceuticals from Overweight to Equal-Weight and set a new price target of $2.00 from $10.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IDRA

Date	Price Target	Rating	Analyst